First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Metastatic Pancreatic Cancer Clinical Trial

Official title:

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04665947
• Other study ID #: 1667622
• Status: Recruiting
• Phase: Early Phase 1
• Start date: December 18, 2020
• Est. completion date: December 2024

Study information

• Verified date: January 2024
• Source: University of California, Davis
• Contact: Julie L Sutcliffe
• Phone: 916-734-5536
• Email: jlsutcliffe[@]ucdavis.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).

Description:

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G /[177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). PET imaging using [68Ga]Ga DOTA-5G will be used to diagnose patients who are eligible for the [177Lu]Lu DOTA-ABM-5G. The overall purpose of this study is to identify the dose limiting toxicity (DLT) and recommended phase 2 dose (RP2D) of [177Lu]Lu DOTA-ABM-5G. A 3+3 study design in is proposed to identify the RP2D of [177Lu]Lu DOTA-ABM-5G. An expansion group will receive the RP2D in order to obtain initial estimates of response and additional information on safety of [177Lu]Lu DOTA-ABM-5G. The hypotheses of this phase I study are that a) [68Ga]Ga DOTA-5G will detect lesions in patients with locally advanced or metastatic pancreas cancer b) the theranostic pair [68Ga]Ga DOTA-5G/ [177Lu]Lu DOTA-ABM-5G will be safe and well tolerated c) we will be able to identify a Recommended Phase 2 Dose (RP2D) for [177Lu]Lu DOTA-ABM-5G therapy to be used in subsequent Phase II trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

[68Ga]Ga DOTA-5G PET/CT Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent document.

2. Age 18 or more years

3. Confirmed presence of locally advanced, unresectable or metastatic pancreatic adenocarcinoma (other pancreatic malignant histologies are excluded) with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion > 1 cm or lymph node > 1.5 cm in short axis)

4. Participant must have documented tumor progression during or following at least one prior systemic regimen as established by CT or MRI scan within 28 days of enrollment

5. Eastern Cooperative Oncology Group Performance Status = 2

6. Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to [68Ga]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to Grade 1 or baseline.

7. Hematologic parameters defined as:

1. Absolute neutrophil count (ANC) = 1000 cells/mm3

2. Platelet count = 100,000/mm3

3. Hemoglobin = 8 g/dL

8. Blood chemistry levels defined as:

1. AST, ALT, alkaline phosphatase = 5 times upper limit of normal (ULN)

2. Total bilirubin = 2 times ULN

3. Creatinine = 2 times ULN

9. Anticipated life expectancy = 3 months

10. Able to remain motionless for up to 30-60 minutes per scan

[177Lu]Lu DOTA-ABM-5G therapy Inclusion Criteria:

1. Completion of entry into [68Ga]Ga DOTA-5G PET study and completion of scan

2. The presence of at least one measurable disease by [68Ga]Ga DOTA-5G PET/CT (SUVmax>2-fold above normal lung or liver)

Exclusion Criteria:

• [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G therapy Exclusion Criteria:

1. Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA)

2. Participants with Class 3 or 4 NYHA Congestive Heart Failure

3. Clinically significant bleeding within two weeks prior to trial entry (e.g. gastrointestinal bleeding, intracranial bleeding)

4. Pregnant or lactating women

5. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks

6. Has an additional active malignancy requiring therapy within the past 2 years

7. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy

8. Psychiatric illness/social situations that would interfere with compliance with study requirements

9. Previous radiation therapy for the treatment of advanced or metastatic disease

10. Cannot undergo PET/CT scanning because of weight limits (350 lbs)

11. INR>1.2; PTT>5 seconds above UNL

Related Conditions & MeSH terms

• Locally Advanced Pancreatic Adenocarcinoma
• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
PET imaging using [68Ga]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the [177Lu]Lu DOTA-ABM-5G.

Locations

Country	Name	City	State
United States	University of California Davis	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	[68Ga]Ga DOTA-5G PET/CT imaging	Assessment of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions in patients with locally advanced or metastatic pancreatic cancer	2 hours from time of injection
Primary	[177Lu]Lu DOTA-ABM-5G dose escalation therapy	Frequency of dose-limiting toxicities (DLT) of [177Lu]Lu DOTA-ABM-5G at escalating dose levels of [177Lu]Lu DOTA-ABM-5G	30 days from time of injection
Secondary	Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G	Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G using SPECT/CT imaging at various timepoints	7-14 days from time of injection